The T. Rowe Price Health Sciences strategy is among the better options available given its strong investment resources, research depth, and framework.
T. Rowe Price Health Sciences I THISX
- NAV / 1-Day Return 88.54 / −0.57 %
- Total Assets 14.4 Bil
-
Adj. Expense Ratio
0.670%
- Expense Ratio 0.670%
- Distribution Fee Level Low
- Share Class Type Institutional
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 500,000
- Status Open
- TTM Yield —
- Turnover 48%
USD | NAV as of Apr 19, 2024 | 1-Day Return as of Apr 19, 2024, 10:18 PM GMT+0
Morningstar’s Analysis THISX
Will THISX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 50.6
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 9.92 | 1.5 Bil | Healthcare |
Aggregate Miscellaneous Equity | 9.50 | 1.5 Bil | — |
UnitedHealth Group Inc | 6.08 | 936.0 Mil | Healthcare |
Intuitive Surgical Inc | 4.13 | 636.2 Mil | Healthcare |
Thermo Fisher Scientific Inc | 4.04 | 623.0 Mil | Healthcare |
Merck & Co Inc | 4.04 | 622.2 Mil | Healthcare |
Stryker Corp | 3.65 | 561.6 Mil | Healthcare |
Elevance Health Inc | 3.56 | 547.8 Mil | Healthcare |
Danaher Corp | 2.96 | 456.1 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 2.69 | 414.6 Mil | Healthcare |